High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study
First-line treatment with ustekinumab demonstrates high treatment-persistence and is associated with substantial rates of clinical, biochemical, and endoscopic remission in patients with IBD.
Authors
- Gregor Novak (ORCID: https://orcid.org/0000-0002-9110-9188)
- David Drobne (ORCID: https://orcid.org/0000-0003-2734-675X)
- Živa Šubic
Institutions
- University of Ljubljana (SI)
- Ljubljana University Medical Centre (SI)
Publication Details
- Journal
- Scandinavian Journal of Gastroenterology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1080/00365521.2025.2597263
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00